Louis Moore Bacon's MYGN Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 210,838 shares of Myriad Genetics, Inc. (MYGN) worth $908,712, representing 0.02% of the portfolio. First purchased in 2013-Q4, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Louis Moore Bacon has maintained a strategic position in MYGN, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2026, adding 218,398 shares. Largest reduction occurred in Q2 2014, reducing 87,902 shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's Myriad Genetics (MYGN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Myriad Genetics (MYGN) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +22,312 | Add 11.83% | 210,838 | $4.31 |
| Q2 2026 | -29,872 | Reduce 13.68% | 188,526 | $5.71 |
| Q1 2026 | +218,398 | New Buy | 218,398 | $4.50 |
| Q3 2024 | -60,000 | Sold Out | 0 | $0.00 |
| Q2 2024 | +60,000 | New Buy | 60,000 | $24.46 |
| Q2 2015 | -20,795 | Sold Out | 0 | $0.00 |
| Q1 2015 | +20,795 | New Buy | 20,795 | $35.39 |
| Q2 2014 | -87,902 | Sold Out | 0 | $0.00 |
| Q1 2014 | -77,098 | Reduce 46.73% | 87,902 | $34.19 |
| Q4 2013 | +165,000 | New Buy | 165,000 | $20.98 |
Louis Moore Bacon's Myriad Genetics Investment FAQs
Louis Moore Bacon first purchased Myriad Genetics, Inc. (MYGN) in Q4 2013, acquiring 165,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held Myriad Genetics, Inc. (MYGN) for 10 quarters since Q4 2013.
Louis Moore Bacon's largest addition to Myriad Genetics, Inc. (MYGN) was in Q1 2026, adding 218,398 shares worth $982,791.
According to the latest 13F filing for Q3 2026, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 210,838 shares of Myriad Genetics, Inc. (MYGN), valued at approximately $908,712.
As of the Q3 2026 filing, Myriad Genetics, Inc. (MYGN) represents approximately 0.02% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in Myriad Genetics, Inc. (MYGN) was 218,398 shares, as reported at the end of Q1 2026.